2015 Revenue: $374.5 million (€342.6 million)
HQ: Lure Cedex, France
Vetoquinol made a major growth push in 2014, when it acquired the animal health business of Canada-based Bioniche Life Sciences. Vetoquinol’s catalog now includes a wide range of products for dogs, cats, livestock and horses. In 2015, its sales for companion animals were particularly strong, rising nearly 11%, thanks to new products such as Upcard, a drug approved in Europe to treat congestive heart failure in dogs. The company also launched Permacyl, a treatment approved in Europe to treat mastitis in cows. Strong sales of new products helped offset a decline in demand for antibiotics stemming from tightened regulations in the U.S. and other countries that are aimed at stopping the rise of drug-resistant infections. Vetoquinol CEO Matthieu Frechin is looking for opportunities to expand the company’s footprint, vowing in its year-end earnings release to remain “proactive” in assessing acquisition opportunities.
Vétoquinol rides reference products sales in second quarter